November 20th, 2026Podcast: Bessel van der Kolk, MD, on Trauma, Attachment, and the Limits of Pharmacotherapy for PTSDBessel van der Kolk, MD, argues that trauma is rooted in attachment and that psychedelic-assisted therapy may help where medications have not.Read more
November 20th, 2026Emestedastat for Alzheimer Disease Falls Short Overall, Signals Subgroup BenefitEmestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.Read more
November 20th, 2026Long-Acting Injectable Antipsychotics: Balancing Evidence, Ethics, and Patient CareIn this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.Read more
November 19th, 2026Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 YearsLeqembi shows lower progression rate in Alzheimer disease over 3 years, shows new data.Read more
November 17th, 2026Mixed Results From Phase 3 Data for AR1001 in Alzheimer DiseaseNew phase 3 data for a PDE-5 inhibitor in Alzheimer disease.Read more
November 16th, 2026Morning Rounds: News From November 9-16Review news from the last week in pharmacology, legislation, and research. Read more
November 13th, 2026Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and SchizophreniaReview the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.Read more
November 12th, 2026Reviewing Roluperidone as Treatment for Negative Symptoms in SchizophreniaMinerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.Read more